Author

Chris Cabell

EARLY AND DURABLE SYMPTOM CONTROL IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD (APD334) IN THE RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 OASIS TRIAL AND OPEN LABEL EXTENSION

Michael Chiorean, Severine Vermeire, Julian Panés, Laurent Peyrin-Biroulet, Jinkun Zhang, Bruce E. Sands, Chris Cabell, Snehal U. Naik, William Sandborn

Long-term efficacy and safety of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study

Severine Vermeire, Julian Panés, Michael Chiorean, Laurent Peyrin-Biroulet, Jinkun Zhang, Bruce E. Sands, Krisztina Lazin, Chris Cabell, Snehal U. Naik, Preston Klassen, William Sandborn

Item 1 - 2 / 2
1